Cell therapies in ovarian cancer.

Détails

ID Serval
serval:BIB_10D5AD530F84
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Cell therapies in ovarian cancer.
Périodique
Therapeutic advances in medical oncology
Auteur(s)
Sarivalasis A., Morotti M., Mulvey A., Imbimbo M., Coukos G.
ISSN
1758-8340 (Print)
ISSN-L
1758-8340
Statut éditorial
Publié
Date de publication
2021
Peer-reviewed
Oui
Volume
13
Pages
17588359211008399
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Résumé
Epithelial ovarian cancer (EOC) is the most important cause of gynecological cancer-related mortality. Despite improvements in medical therapies, particularly with the incorporation of drugs targeting homologous recombination deficiency, EOC survival rates remain low. Adoptive cell therapy (ACT) is a personalized form of immunotherapy in which autologous lymphocytes are expanded, manipulated ex vivo, and re-infused into patients to mediate cancer rejection. This highly promising novel approach with curative potential encompasses multiple strategies, including the adoptive transfer of tumor-infiltrating lymphocytes, natural killer cells, or engineered immune components such as chimeric antigen receptor (CAR) constructs and engineered T-cell receptors. Technical advances in genomics and immuno-engineering have made possible neoantigen-based ACT strategies, as well as CAR-T cells with increased cell persistence and intratumoral trafficking, which have the potential to broaden the opportunity for patients with EOC. Furthermore, dendritic cell-based immunotherapies have been tested in patients with EOC with modest but encouraging results, while the combination of DC-based vaccination as a priming modality for other cancer therapies has shown encouraging results. In this manuscript, we provide a clinically oriented historical overview of various forms of cell therapies for the treatment of EOC, with an emphasis on T-cell therapy.
Mots-clé
adoptive cell therapy (ACT), cancer immunotherapy, neoantigens, ovarian cancer, tumor-infiltrating lymphocyte (TIL)
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/05/2021 14:29
Dernière modification de la notice
04/09/2021 6:34
Données d'usage